Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)

NCT00138086 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00138086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00138086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)
Lead sponsor
Lymphoma Study Association
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
March 31, 2009
Enrollment
75
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma